|
1
|
Vergote I, Coleman RL, Pignata S, Bookman MA, Marth C, Herzog TJ, Gonzalez-Martin A, Copeland LJ. Joint ENGOT and GOG Foundation requirements for trials with industry partners. Gynecol Oncol 2019; 154:255-258. [PMID: 31331494 DOI: 10.1016/j.ygyno.2019.04.677] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 04/16/2019] [Accepted: 04/21/2019] [Indexed: 10/26/2022]
Affiliation(s)
- Ignace Vergote
- ENGOT/BGOG and University Hospital Leuven, Gynaecological Oncology, Leuven Cancer Institute, Herestraat 49, 3000 Leuven, Belgium, European Union.
| | - Robert L Coleman
- GOG-F and Gynecologic Oncology & Reproductive Medicine, University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA
| | - Sandro Pignata
- ENGOT/MITO Istituto Nazionale Tumori IRCCS Fondazione Pascale Napoli, Italy
| | - Michael A Bookman
- GOG-F and Gynecologic Oncology Therapeutics, Kaiser Permanente San Francisco, San Francisco, USA
| | - Christian Marth
- ENGOT/A-AGO and Obstetrics and Gynecology, Innsbruck Medical University, Innsbruck, Austria
| | - Thomas J Herzog
- GOG-F and Gynecologic Oncology, University of Cincinnati, Cincinnati, Ohio, USA
| | | | - Larry J Copeland
- GOG-F and Gynecologic Oncology, Ohio State University Wexner Medical Center and JamesCare Gynecologic Oncology at Mill Run, Columbus, Ohio, USA
| | | | | |
Collapse
|